Cantor Fitzgerald Inc.: The Axsome Therapeutics (AXSM.US) rating was reaffirmed and adjusted from an increase holdings to an increase rating, with a target price of $107.00.
坎托菲茨杰拉德公司：重申Axsome Therapeutics(AXSM.US)评级，由增持调整至增持评级, 目标价107.00美元。
Cantor Fitzgerald Inc.: The Axsome Therapeutics (AXSM.US) rating was reaffirmed and adjusted from an increase holdings to an increase rating, with a target price of $107.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.